AYVAKIT was generally well tolerated in PIONEER1

ADVERSE REACTIONS OCCURRING IN PATIENTS WITH ISM DURING THE PIONEER TRIAL1

  • Serious adverse reactions occurred in 1 patient (0.7%) who received AYVAKIT due to pelvic hematoma1
  • Permanent discontinuation of AYVAKIT due to an adverse reaction occurred in 1 patient (0.7%) due to dyspnea and dizziness1
  • Dosage interruptions of AYVAKIT due to an adverse reaction occurred in 5% of patients1
24 week safety table

a Adverse reactions that occurred in ≥5% of AYVAKIT-treated patients and ≥2% more than placebo-treated patients.1

b Per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.1

c Eye edema includes periorbital edema, eye edema, swelling of eyelid, orbital edema, eye swelling, eyelid edema, and eyelid ptosis.1

d Term includes several similar terms.1

e Respiratory tract infection includes pneumonia, upper respiratory tract infection, bronchitis, and respiratory tract infection.1

f Hematoma includes contusion, hematoma, and pelvic hematoma.1

g Hemorrhage includes epistaxis, gingival bleeding, hematochezia, rectal hemorrhage, and retinal hemorrhage.1

BSC=best supportive care; ISM=indolent systemic mastocytosis.

Learn more about once-daily dosing
with AYVAKIT

DOSING
Construction worker items on a table

References: 1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024. 2. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2024.